Planegg / Martinsried (13.01.2021) – The Medigene AG (Medigene, FWB: MDG1, Prime Standard), an immuno-oncology company with clinical projects focused on the development of T-cell-directed cancer therapies, has received patents for certain technologies in key areas, including the USA and Europe. Patent applications in other areas are pending.
TCR library (US10,858,760)
This US patent, from whose family a patent was already granted in Europe in 2019 (EP3303591), protects Medigenes Building block library for T cell receptors (T cell receptor, TCR), which enables the rapid reconstruction and analysis of newly discovered human TCR sequences.
Two TCR protein chains, alpha and beta, together determine the specificity of the TCR. The patent comprises a library of 92 TCR constructs (including all 45 different TCR-alpha chains and all 47 different TCR-beta chains) which are required as starting material for the recombinant expression of any TCR. The constructs also contain design elements for the flexible exchange of any other TCR regions and adapter sequences that make it possible to introduce reconstructed TCRs into recipient T cells in various ways.
This library enables rapid, high throughput reconstruction of a large number of TCR candidates that are specific for the desired antigens. The library also offers tools to produce patient-specific TCRs that are directed against certain mutations. The efficient production of many TCRs in parallel makes it possible to quickly identify the sequences with the best functionality and to select them for cellular TCR-T therapies.
The European Patent Office intends to grant a European patent covering the CrossTAg-1 technology. Patents for this technology were already granted in Japan (JP6676759), Australia (AU2016374873) and New Zealand (NZ741954) last year.
This technology enables the cross-presentation of antigens on molecules of the Major histocompatibility complex (Major Histocompatibility Complex, MHC) of classes I and II (in humans also “Humane Leukocyte antigens“, Called HLA), thereby stimulating both killer and helper T cells. These important subsets of T cells play key roles in immune responses, including those against cancer.
CrossTAg-1 technology ensures that short peptides of an antigen are effectively processed through cellular pathways for both Class I and Class II HLA presentation. Hence believe Medigene also that the use of the CrossTAgTechnology could potentially improve T cell responses to mRNA-based vaccines.
The CrossTAg-2 patent, which was granted last year in Japan (JP6697562), Australia (AU2016374874) and New Zealand (NZ741955) and now in the USA, covers the use of the CrossTAg-Technology in dendritic cells (dendritic cells, DCs) and DC vaccines. This technology effectively stimulates both killer and helper T cells against specific targets, which enables very broad immune activation.
The Medigene Immunotherapies GmbH and Helmholtz Zentrum München are co-applicants and the CrossTAg-Patents fall under the license agreement concluded with the Helmholtz Zentrum München.
Prof. Dolores Schendel, Chairwoman and Scientific Director of Medigene: “The growing patent portfolio of Medigene reflects the broad applicability of their continuous innovations and scientific excellence in the field of therapeutic T cells. Building a patent portfolio that covers these technologies in key commercial markets is critical to protecting the value of our innovation investments. We believe that our technologies can make an important contribution to overcoming the ongoing challenges in clinical medicine for solid tumors and infectious diseases. “
— End of press release —
The Medigene AG (FWB: MDG1, Prime Standard, ISIN DE000A1X3W00,) is a listed biotechnology company with its headquarters in Martinsried near Munich. The company develops highly innovative immunotherapies for the treatment of various types and stages of cancer. Doing so concentrates Medigene on personalized, T-cell-directed therapy approaches. Corresponding projects are in preclinical and clinical development.
More information at www.medigene.de
over Medigenes TCR-Ts
The TCR technology aims to equip the patient’s own T cells with tumor-specific T cell receptors (T. cell receptor, TCR). The T cells modified with regard to their receptor are thus able to recognize tumor cells and to destroy them effectively. This immunotherapeutic approach tries to overcome the tolerance towards cancer cells and tumor-induced immunosuppression in the patient by activating and modifying the patient’s T cells outside the body (ex vivo). The TCR-T therapy is used for finding a larger number of possible tumor antigens compared to other T-cell-based immunotherapies, such as the chimeric antigen receptor T-cells (chimeric antigen receptor T cells, CAR-Ts), entwickelt.
Medigene is conducting a first clinical phase I / II study with its first own TCR-T candidate MDG1011 for the blood cancer indications AML and MDS as well as a second clinical phase I study with MDG1021 in patients who after allogeneic (foreign) hematopoietic stem cell transplantation ( allo-HSCT) have relapse or persistent blood cancer. Continue to build Medigene a pipeline of TCRs and cooperates with bluebird bio, Inc. and Cytovant Sciences HK Ltd. with a focus on solid tumor indications.
over Medigenes DC vaccines
Next Medigenes With a focus on T-cell receptor-modified T cells (TCR-Ts), the company has developed a new generation of antigen-specific dendritic cell vaccines.
Dendritic Zellen (dendritic cell, DC) are able to take up antigens, process them and present them on their cell surface in such a way that antigen-specific T cells are activated and thereby stimulated to maturation and division. This enables the T cells to recognize and eliminate tumor cells that have the same antigen on their surface. Dendritic cells can also activate natural killer cells (NK cells) to attack tumor cells. The scientific team at Medigene has developed new, fast and effective methods to allow autologous, ie the body’s own, dendritic cells to mature and to prepare them in such a way that they generate a particularly strong T-cell and NK-cell immune response. The dendritic cells can be provided with different tumor antigens in order to treat different types of tumors. Since an immune response builds up over the entire duration of the administration of the DC vaccine, this form of therapy is particularly suitable for patients who suffer from a tumor disease, but chemotherapy has reduced it to such an extent that the focus is on preventing the tumor from breaking out again .
This release contains certain forward-looking statements. These reflect the opinion of Medigene as of the date of this announcement wider. The from Medigene Results actually achieved may differ materially from the statements made in the forward-looking statements. Medigene is not obliged to update forward-looking statements. Medigene® is a brand of Medigene AG. This trademark may be owned or licensed for selected countries.
Dr. Gary Waanders, Dr. Anna Niedl
Tel.: +49 89 2000 3333 01
E-mail: [email protected]
Emitter: Medigene AG
Address: Lochhamer Strasse 11, 82152 Planegg / Martinsried
Contact Person: Medigene PR / IR
Tel.: +49 89 2000 3333 01
E-mail: [email protected]
ISIN(s): DE000A1X3W00 (Aktie)
Exchanges: Regulated Market in Frankfurt; Regulated Unofficial Market in Stuttgart, Regulated Unofficial Market in Munich, Regulated Unofficial Market in Hamburg, Regulated Unofficial Market in Düsseldorf, Regulated Unofficial Market in Hanover; Regulated Unofficial Market in Berlin, Tradegate